Position in ZYME
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$2,540,032
+$744,405 QoQ
Shares Held
101,439
+48.7% QoQ
Ownership
0.139%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 33%
Shared 0%
None 67%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Fisher Asset Management, LLC holds $671,245,647 across 48 Biotechnology names. ZYME ranks #35 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
1,113,568 | $69,820,713 | |
| 2 | CYTK |
Cytokinetics Inc
|
768,264 | $50,636,280 | |
| 3 | RCUS |
Arcus Biosciences, Inc.
|
2,190,404 | $47,312,726 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
2,436,895 | $46,788,384 | |
| 5 | VRDN |
Viridian Therapeutics, Inc.\DE
|
1,768,295 | $34,587,850 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
1,013,648 | $32,152,914 | |
| 7 | CGON |
CG Oncology, Inc.
|
465,033 | $31,473,433 | |
| 8 | IDYA |
IDEAYA Biosciences, Inc.
|
882,699 | $29,411,530 |
All Filings in ZYME
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,540,032 | 101,439 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $1,795,627 | 68,197 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $1,229,315 | 71,974 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $903,336 | 71,979 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $857,210 | 71,974 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $931,104 | 63,600 | Shares | Defined | 2025-02-05 | |
| 2024-09-30 | $798,180 | 63,600 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $541,236 | 63,600 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||